Enzymatica ABFRA:EN9 +4.55%36 PS Ratio is 9.78 as of Jul. 12, 2026, which is 3% above its 10-year median of 9.53. GuruFocus rates FRA:EN9 with a GF Score™ of 36/100 and a GF Value™ of €0.16 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Enzymatica AB ranks worse than 88.27% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Enzymatica AB's share price is €0.1955.
Enzymatica AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.02. Hence, Enzymatica AB's PS Ratio for today is 9.78.
The historical rank and industry rank for Enzymatica AB's PS Ratio or its related term are showing as below:
FRA:EN9'
s PS Ratio Range Over the Past 10 Years
Min: 2.29 Med: 9.53 Max: 33.74
Current: 11.32
During the past 13 years, Enzymatica AB's highest PS Ratio was 33.74. The lowest was 2.29. And the median was 9.53.
FRA:EN9's PS Ratio is ranked worse than 88.27% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs FRA:EN9: 11.32
Enzymatica AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Enzymatica AB was -1.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -8.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -18.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -11.60% per year.
During the past 13 years, Enzymatica AB's highest 3-Year average Revenue per Share Growth Rate was 209.10% per year. The lowest was -26.40% per year. And the median was -8.30% per year.
Back to Basics: PS Ratio
Enzymatica AB (FRA:EN9) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Enzymatica AB PS Ratio Related Terms
Enzymatica AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Enzymatica AB's Share Price of today is €0.1955. Enzymatica AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Enzymatica AB (FRA:EN9) has a PS Ratio of 9.78 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Enzymatica AB and its competitors. This is near median its historical median of 9.53. Over the past decade, Enzymatica AB's PS Ratio has ranged from 2.29 to 33.74. According to the industry distribution chart, Enzymatica AB ranks #843 out of 955 companies in the Drug Manufacturers industry, placing it in the top 88.3%.
Is Enzymatica AB's PS Ratio too high?
Enzymatica AB's current PS Ratio of 9.78 is near median its 10-year median of 9.53. Over the past 10 years, this metric has ranged from a low of 2.29 to a high of 33.74. The Drug Manufacturers industry median PS Ratio is 2.30. Enzymatica AB's value of 9.78 is 325.2% above this industry median. Based on the distribution chart, Enzymatica AB ranks #843 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enzymatica AB has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #843 out of 955 companies for PS Ratio. This places Enzymatica AB in the lower half of its industry. The industry median PS Ratio is 2.30. Enzymatica AB's value of 9.78 is 325.2% above this benchmark. Historically, Enzymatica AB's own PS Ratio has ranged from 2.29 to 33.74 over the past decade. While the company's 10-year median is 9.53 vs. the industry median of 2.30, Enzymatica AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enzymatica AB's current PS Ratio of 9.78 is 325.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current PS Ratio is 9.78, which is near median its own 10-year median of 9.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.16, compared to a current price of €0.20 — trading 22.2% above its estimated fair value. The current PS Ratio is 9.78, which is near median its 10-year median of 9.53 and 325.2% above the Drug Manufacturers industry median of 2.30. Enzymatica AB's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current PS Ratio is 9.78 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (FRA:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued.
The current stock price of €0.20 is trading 22.2% above its estimated GF Value™ of €0.16.
GuruFocus considers Enzymatica AB to be Modestly Overvalued.
Key valuation signals for FRA:EN9:
PS Ratio: 9.78 (near median its 10-year median of 9.53)
GF Value™: €0.16 vs. price of €0.20 (22.2% above fair value)
Industry Position: 325.2% above the Drug Manufacturers median (#843 of 955)
No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
36GF Score
Get the complete analysis for FRA:EN9
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EN9 has been successfully added to your 
